Project Grant HT94252310465

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

The National Institute of Neurological Disorders and Stroke awarded Yale University $461,197 on March 17, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop plasma-based biomarkers for stratifying amyotrophic lateral sclerosis patients into distinct molecular subtypes. The project leverages a collection of matched plasma samples and autopsied motor cortices from fifty ALS patients previously categorized into three...

This Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop neuronal exosome-based biomarkers for the diagnosis and disease progression of amyotrophic lateral sclerosis (ALS). The total award amount is $1,181,251.00, with a performance period from April 15, 2025 to April 14, 2028. The principal investigator for this grant is the University of California, Los Angeles (UCLA), which has a...

The National Institute on Aging awarded Redwood Neuro Inc. $506,061 on September 15, 2025, under the Aging Research program (CFDA 93.866) to develop the SIMOLISA platform, an ultra-sensitive blood-based assay for early detection and longitudinal monitoring of Alzheimer's disease biomarkers. Redwood Neuro will establish and validate a comprehensive seven-biomarker panel (phosphorylated tau variants P-TAU-181, P-TAU-217, and P-TAU-231; total tau; amyloid-beta 42 and 40; and neurofilament light)...

The National Institute on Aging awarded The Salk Institute for Biological Studies $772,971 on September 1, 2026, for multi-omics analysis of astrocytes in Alzheimer's disease to identify targets to prevent synapse loss under the Aging Research program (CFDA 93.866). The research tests the hypothesis that alterations to synapse-supportive roles of astrocytes in Alzheimer's disease contribute to synaptic dysfunction and disease pathogenesis. The project employs in vivo cell-type specific RNA...

The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $528,643 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate inhibition of specific kinases in the p38 MAPK pathway module as a potential treatment for genetic forms of amyotrophic lateral sclerosis (ALS). The project focuses on axonal degeneration, an early pathological event in ALS. Prior research documented...

The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded Emory University $156,500 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to generate and characterize a novel conditional SPTLC1 mouse model investigating sphingolipid dysregulation in amyotrophic lateral sclerosis. The project will develop the first...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will investigate the role of glial fibrillary acidic protein (GFAP) upregulation in reactive astrocytes and its impact on tripartite excitatory synapses in a tauopathy mouse model of Alzheimer's disease. Specifically, the $452,550 award to The General Hospital Corporation (dba Massachusetts General Hospital) will overexpress GFAP in astrocytes and blunt GFAP upregulation to evaluate changes in the...

The National Institute of Neurological Disorders and Stroke awarded Regents of the University of Michigan $619,212 on July 6, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds transcriptomics research on blood samples in amyotrophic lateral sclerosis (ALS) to advance diagnosis, prognosis, drug discovery, and identification of molecular disease subtypes. The research addresses delayed ALS diagnosis (typically over a...

The National Institute on Aging awarded the University of Texas at Dallas $761,537 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate a novel astrocyte endfoot protein arising from translational readthrough and its role in Alzheimer's disease pathology. The research develops loss-of-function and gain-of-function mouse models to characterize AQP4X, an extended isoform of aquaporin 4 that arises when approximately 20 percent of translating ribosomes continue past...